MK 287

• Description:

  MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR) . MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis[1].

• UNSPSC:

  12352005

• Target:

  Platelet-activating Factor Receptor (PAFR)

• Related Pathways:

  GPCR/G Protein

• Field of Research:

  Cardiovascular Disease

• Smiles:

  CCCOC1=C(C=C([C@H]2O[C@H](C3=CC(OC)=C(C(OC)=C3)OC)CC2)C=C1OC)S(CCO)(=O)=O

• Molecular Formula:

  C25H34O9S

• Molecular Weight:

  510.60

• References & Citations:

  [1]Hwang SB, et al. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor. J Lipid Mediat. 1993 Jun;7 (2) :115-34.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [135947-75-0]